Annual Cash & Cash Equivalents
$16.33 M
-$16.76 M-50.64%
December 31, 2023
Summary
- As of February 8, 2025, KTTA annual cash & cash equivalents is $16.33 million, with the most recent change of -$16.76 million (-50.64%) on December 31, 2023.
- During the last 3 years, KTTA annual cash & cash equivalents has risen by +$16.09 million (+6601.31%).
- KTTA annual cash & cash equivalents is now -69.17% below its all-time high of $52.97 million, reached on December 31, 2021.
Performance
KTTA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$9.36 M
+$1.39 M+17.49%
September 30, 2024
Summary
- As of February 8, 2025, KTTA quarterly cash and cash equivalents is $9.36 million, with the most recent change of +$1.39 million (+17.49%) on September 30, 2024.
- Over the past year, KTTA quarterly cash and cash equivalents has increased by +$1.39 million (+17.49%).
- KTTA quarterly cash and cash equivalents is now -82.33% below its all-time high of $52.97 million, reached on December 31, 2021.
Performance
KTTA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
KTTA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -50.6% | +17.5% |
| 3 y3 years | +6601.3% | -77.9% |
| 5 y5 years | +6601.3% | -77.9% |
KTTA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -69.2% | at low | -82.3% | +17.5% |
| 5 y | 5-year | -69.2% | +6601.3% | -82.3% | +1545.2% |
| alltime | all time | -69.2% | +6601.3% | -82.3% | +1545.2% |
Pasithea Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $9.36 M(+17.5%) |
| Jun 2024 | - | $7.97 M(-33.7%) |
| Mar 2024 | - | $12.01 M(-26.5%) |
| Dec 2023 | $16.33 M(-50.6%) | $16.33 M(-16.6%) |
| Sep 2023 | - | $19.58 M(-26.5%) |
| Jun 2023 | - | $26.65 M(-10.9%) |
| Mar 2023 | - | $29.91 M(-9.6%) |
| Dec 2022 | $33.09 M | $33.09 M(-22.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $42.40 M(-11.6%) |
| Jun 2022 | - | $47.94 M(-4.7%) |
| Mar 2022 | - | $50.32 M(-5.0%) |
| Dec 2021 | $52.97 M(>+9900.0%) | $52.97 M(+157.6%) |
| Sep 2021 | - | $20.57 M(+3514.3%) |
| Jun 2021 | - | $569.00 K(-46.9%) |
| Mar 2021 | - | $1.07 M |
| Dec 2020 | $243.70 K | - |
FAQ
- What is Pasithea Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pasithea Therapeutics?
- What is Pasithea Therapeutics annual cash & cash equivalents year-on-year change?
- What is Pasithea Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Pasithea Therapeutics?
- What is Pasithea Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Pasithea Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of KTTA is $16.33 M
What is the all time high annual cash & cash equivalents for Pasithea Therapeutics?
Pasithea Therapeutics all-time high annual cash & cash equivalents is $52.97 M
What is Pasithea Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, KTTA annual cash & cash equivalents has changed by -$16.76 M (-50.64%)
What is Pasithea Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of KTTA is $9.36 M
What is the all time high quarterly cash and cash equivalents for Pasithea Therapeutics?
Pasithea Therapeutics all-time high quarterly cash and cash equivalents is $52.97 M
What is Pasithea Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, KTTA quarterly cash and cash equivalents has changed by +$1.39 M (+17.49%)